Sarepta Therapeutics (SRPT) Upward-Ride Session; Stifel Sees Potential In Dycom Industries (DY)


Sarepta Therapeutics, Inc. (Nasdaq:SRPT) stock climbed $1.55 (or +8.81%) to $19.15, with a total volume of 7,477,212 shares traded on Friday. There appears to be no relevant recent information from the biopharmaceutical company that may explain the stock’s movement

The U.S. Food and Drug Administration’s (FDA) target review date for eteplirsen – Sarepta’s lead product candidate for the treatment of Duchenne muscular dystrophy – is currently scheduled for May 26, 2016.

Sarepta Therapeutics, which focuses on the discovery and development of RNA-based therapeutics, has 45.77M Shares Outstanding, Market Capitalization (intraday) of $876.59M and SRPT stock 52-week range is between $8.00 and $41.97 per share



Shares of Dycom Industries, Inc. (NYSE:DY) surged $2.22 (or +3.18%) to $71.97 on Friday’s trading session after brokerage firm Stifel maintained a Buy rating while raising its price target on the company’s stock from $80.00 to $86.00.

The company expects to release its third quarter fiscal 2016 earnings report on Tuesday, May 24, after the closing bell.

Dycom Industries, a leading provider of specialty contracting services throughout the United States and in Canada, has 31.34M Shares Outstanding, Market Capitalization (intraday) of $2.26B and DY stock one-year range is between $47.10 and $90.82 per share


Disclaimer: The disclaimer is to be read and fully understood before using our site, or joining our email list. GalaxyStocks is not a registered investment adviser. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Investors should always conduct their own due diligence with any potential investment, with independent research and other professional advice. Read full disclaimer at